Show simple item record

dc.contributor.authorMok, T
dc.contributor.authorKim, D
dc.contributor.authorWu, YL
dc.contributor.authorNakagawa, K
dc.contributor.authorMekhail, T
dc.contributor.authorFelip, E
dc.contributor.authorCappuzzo, F
dc.contributor.authorPaolini, J
dc.contributor.authorUsari, T
dc.contributor.authorWilner, K
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorSolomon, B
dc.date.accessioned2017-11-22T21:55:36Z
dc.date.available2017-11-22T21:55:36Z
dc.date.issued2017
dc.identifier.citationLBA50 Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: updated results from PROFILE 1014. 2017, 28(suppl_5): Ann Oncolen
dc.identifier.urihttp://hdl.handle.net/10541/620671
dc.titleLBA50 Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK plus lung cancer: updated results from PROFILE 1014.
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment Of Clinical Oncology, The Chinese University of Hong Kong, 000 - Hong Kong/CNen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record